Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer

The Slit-Robo pathway has shown to be altered in several malignant diseases. However, its role in bladder cancer is poorly understood. Therefore, we aimed to assess the tissue expression of Robo1 and Robo4 as well as their ligand Slit2 in different stages of bladder cancer to explore possible changes of Slit-Robo signalling during the progression of bladder cancer. Robo1, Robo4 and Slit2 gene expressions were analyzed in 92 frozen bladder cancer tissue samples by using reverse transcription quantitative real-time PCR. Immunohistochemical analyses were performed on 149 formalin-fixed and paraffin-embedded bladder cancer tissue samples. Results were correlated with the clinical and follow-up data by performing both univariable and multivariable analyses. Robo1 and Robo4 nuclear staining intensitiy was significantly higher in low stage and low grade bladder cancer. Elevated Robo1 nuclear staining was associated with better disease-specific survival (DSS) (p = 0.045). Similarly, stronger Robo4 nuclear staining tended to be associated with longer DSS (p = 0.061). We found higher Robo1 and Slit2 gene expression levels in advanced stages of bladder cancer (p = 0.007 and p < 0.001). High Slit2 gene expression was correlated with significantly shorter DSS (p < 0.005), while Robo1 and Robo4 gene expressions were not associated with patients' prognosis. Our results demonstrate that the nuclear expression of Robo1 and Robo4 is associated with a favourable prognosis suggesting that its translocation into the nucleus represent a posttranslational regulation process which may exhibit an antitumor effect in bladder cancer.

Pathology oncology research : POR. 2018 Jul 17 [Epub ahead of print]

Ulrich Krafft, Henning Reis, Marc Ingenwerth, Ilona Kovalszky, Markus Becker, Christian Niedworok, Christopher Darr, Péter Nyirády, Boris Hadaschik, Tibor Szarvas

Department of Urology, Faculty of Medicine, University Duisburg-Essen, Hufelandstr 55, 45147, Essen, Germany., Institute of Pathology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany., 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary., Department of Urology, Semmelweis University, Üllöi út 78/b, Budapest, 1082, Hungary., Department of Urology, Faculty of Medicine, University Duisburg-Essen, Hufelandstr 55, 45147, Essen, Germany. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe